Lupin's Diazepam ANDA220365 Receives Approval Status from FDA
Lupin's ANDA for Diazepam has received an approval status (AP) from the FDA.
Published: July 30, 2026
Updated: July 30, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Anxiolytic
Company: Lupin
Asset: Diazepam
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Lupin
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval status for Lupin's Diazepam ANDA220365 is significant as it positions Lupin to enhance its competitive standing in the anxiolytic market. This development necessitates careful monitoring of market dynamics and potential shifts in pricing strategies as Lupin prepares for market entry.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the final approval and market launch timelines for Diazepam.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.